Login to Your Account



IN THE CLINIC NEWS
SHANGHAI – For a small start-up with only two and a half years under its belt, Suzhou Connect Biopharmaceuticals Inc., of Suzhou, Jiangsu, is understandably pleased to be kicking off its phase I trials for CBP-307 in Australia.
WORTH A TRY AS PHASE III GOES ON

With encouraging interim phase II data in hand and a large phase III trial under way, Celldex Therapeutics Inc. is making plans to talk with regulators about the chances for approval of rindopepimut (rindo), an immunotherapy vaccine targeting epidermal growth factor variant III (EGFRvIII) in glioblastoma multiforme (GBM).

HONG KONG – A Chinese vaccine and blood product maker is taking steps into the biosimilar market with four monoclonal antibody (MAbs) biosimilar drugs.
More IN THE CLINIC Headlines

Cast Your Vote

Has biotech’s bubble burst?: